What Tepezza treats.
- Thyroid eye disease (active and chronic)
- Graves’ ophthalmopathy
The mechanism.
Tepezza (teprotumumab) blocks the insulin-like growth factor 1 receptor (IGF-1R), which drives the inflammation and tissue expansion behind the eyes in thyroid eye disease. By interrupting this pathway, Tepezza reduces eye bulging (proptosis), double vision, and orbital inflammation.
Your Tepezza infusion experience.
Tepezza is given as a series of 8 infusions, one every 3 weeks. The first infusion lasts about 90 minutes, with subsequent infusions reduced to 60 minutes if tolerated. Hearing changes, hyperglycemia, and infusion reactions are monitored throughout treatment.
Insurance & out-of-pocket cost.
Tepezza is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.